文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗白血病

BCR-ABL1阴性MPN急变期移植结局与de novo AML及MDS后AML的比较

Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
PubMed 文献 · Blood Adv · 2020-01-01

该研究基于CIBMTR数据库,比较177例BCR-ABL1阴性MPN急变期(MPN-BP)患者与4749例de novo AML及1104例MDS后AML患者接受异基因造血细胞移植(HCT)的结局。多因素分析显示,MPN-BP缓解期患者OS劣于de novo AML缓解期(HR 1.40),且复发率更高(HR 2.18);MPN-BP患者OS也劣于MDS后AML(HR 1.19),复发增加(HR 1.60)。

要点

  • MPN-BP缓解期移植后OS劣于de novo AML缓解期,主因复发率更高。
  • MPN-BP移植后OS及复发均劣于MDS后AML。
  • 外周血移植物与MPN-BP及MDS后AML复发降低相关(HR 0.70)。

核心结论

  • MPN-BP患者HCT后生存劣于de novo AML缓解期及MDS后AML,主要因复发率增加。
  • 需优化复发预防策略以改善MPN-BP的HCT结局。

研究设计与样本

  • 基于CIBMTR数据库的回顾性比较研究。
  • 比较177例MPN-BP与4749例de novo AML及1104例MDS后AML的HCT结局,采用多因素回归分析。

主要发现

  • MPN-BP与de novo AML活动期白血病患者相比,OS及复发无差异。
  • MPN-BP缓解期患者OS劣于de novo AML缓解期(HR 1.40,95%CI 1.12-1.76),复发率更高(HR 2.18,95%CI 1.69-2.80)。
  • MPN-BP患者OS劣于MDS后AML(HR 1.19,95%CI 1.00-1.43),复发增加(HR 1.60,95%CI 1.31-1.96)。
  • 不良细胞遗传学与两种比较中复发增加相关。
  • 外周血移植物与MPN-BP及MDS后AML复发降低相关(HR 0.70,95%CI 0.57-0.86)。

临床怎么用

  • MPN-BP患者HCT后应重点关注复发预防策略。
  • 选择外周血移植物可能降低MPN-BP及MDS后AML移植后复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1- myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT outcomes in 177 MPN-BP patients with 4749 patients with de novo AML, and 1104 patients with post-MDS AML, using multivariate regression analysis in 2 separate comparisons. In a multivariate Cox model, no difference in overall survival (OS) or relapse was observed in patients with MPN-BP vs de novo AML with active leukemia at HCT. Patients with MPN-BP in remission had inferior OS in comparison with de novo AML in remission (hazard ratio [HR], 1.40 [95% confidence interval [CI], 1.12-1.76]) due to higher relapse rate (HR, 2.18 [95% CI, 1.69-2.80]). MPN-BP patients had inferior OS (HR, 1.19 [95% CI, 1.00-1.43]) and increased relapse (HR, 1.60 [95% CI, 1.31-1.96]) compared with post-MDS AML. Poor-risk cytogenetics were associated with increased relapse in both comparisons. Peripheral blood grafts were associated with decreased relapse in MPN-BP and post-MDS AML (HR, 0.70 [95% CI, 0.57-0.86]). Nonrelapse mortality (NRM) was similar between MPN-BP vs de novo AML, and MPN-BP vs post-MDS AML. Total-body irradiation-based myeloablative conditioning was associated with higher NRM in both comparisons. Survival of MPN-BP after HCT is inferior to de novo AML in remission and post-MDS AML due to increased relapse. Relapse-prevention strategies are required to optimize HCT outcomes in MPN-BP.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gupta V, Kim S, Hu ZH, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. Blood Adv. 2020. PMID: 33007075. doi:10.1182/bloodadvances.2020002621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。